4. Intangible Assets, Goodwill and Other

12 Months Ended

Dec. 31, 2011

Intangible Assets Goodwill and Other [Abstract]

Goodwill and Intangible Assets Disclosure

4. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):



	2011									2010
	Life Science			Clinical Diagnostics			Total			Life Science			Clinical Diagnostics		Total
Balances as of January 1:
Goodwill	$	70.7		$	320.5		$	391.2		$	70.7		$	284.1	$	354.8
Accumulated impairment losses	(27.2		)	—			(27.2		)	(27.2		)	—		(27.2		)
Goodwill, net	43.5			320.5			364.0			43.5			284.1		327.6
Acquisitions	106.1			—			106.1			—			12.8		12.8
Currency fluctuations	—			(1.2		)	(1.2		)	—			23.6		23.6
Balances as of December 31:
Goodwill	176.8			319.3			496.1			70.7			320.5		391.2
Accumulated impairment losses	(27.2		)	—			(27.2		)	(27.2		)	—		(27.2		)
Goodwill, net	$	149.6		$	319.3		$	468.9		$	43.5		$	320.5	$	364.0

As part of the acquisition of QuantaLife in October 2011 (see Note 2), we recorded $106.1 million of goodwill and $94.7 million of definite-lived intangible assets considered know how. The determination of the fair value of net assets acquired of QuantaLife (see Note 2) was based upon valuation information, estimates and assumptions available at October 4, 2011. We are still finalizing our analysis of a limited number of acquired tax attributes which could affect the fair values of certain deferred tax assets and goodwill. As a result, as of December 31, 2011, our accounting for the acquisition was preliminary.

In conjunction with the acquisition of certain businesses of Biotest in January 2010 (see Note 2), we recorded $12.8 million of goodwill and $21.2 million of intangible assets: $7.5 million of customer relationships, $9.5 million of developed product technology and $4.2 million of tradenames.

Other than goodwill, we have no significant intangible assets with indefinite lives. Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):



	December 31, 2011
	Average Remaining Life (years)	Purchase Price		Accumulated Amortization			Net Carrying Amount
Customer relationships/lists	1-12	$	98.7	$	(30.9	)	$	67.8
Know how	1-14	187.0		(45.7		)	141.3
Developed product technology	1-11	47.6		(24.6		)	23.0
Licenses	1-9	35.6		(15.7		)	19.9
Tradenames	1-10	29.5		(22.1		)	7.4
Covenants not to compete	1-7	5.8		(5.7		)	0.1
Patents	—	1.0		(1.0		)	—
Other	—	0.1		(0.1		)	—
		$	405.3	$	(145.8	)	$	259.5



	December 31, 2010
	Average Remaining Life (years)	Purchase Price		Accumulated Amortization			Net Carrying Amount
Customer relationships/lists	1-13	$	102.3	$	(24.8	)	$	77.5
Know how	1-6	92.6		(33.0		)	59.6
Developed product technology	1-11	47.9		(19.2		)	28.7
Licenses	1-10	35.4		(12.2		)	23.2
Tradenames	2-12	29.5		(15.9		)	13.6
Covenants not to compete	1-8	5.9		(4.6		)	1.3
Patents	—	1.0		(1.0		)	—
Other	1	0.1		(0.1		)	—
		$	314.7	$	(110.8	)	$	203.9

In 2009, a $3.8 million impairment loss related to intangible assets was recorded in the Life Science segment. The intangible asset impairment related to the developed technology intangible assets of certain product lines that were acquired in 2006. No material impairment losses related to intangible assets were recorded in 2011 or 2010.

Amortization expense related to purchased intangible assets for the years ended December 31, 2011, 2010 and 2009 was $39.1 million, $33.7 million and $31.7 million, respectively. Estimated future amortization expense (based on existing intangible assets) for the years ending December 31, 2012, 2013, 2014, 2015 and 2016 is $43.9 million, $39.2 million, $36.0 million, $33.0 million and $29.5 million, respectively.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details